Chinese biotech QL Biopharm reported that its once-monthly GLP-1 receptor agonist, zovaglutide (ZT-002), met primary and secondary endpoints in a randomized, placebo-controlled phase II obesity trial. The trial enrolled overweight and obese patients who received doses up to 160 mg monthly or biweekly over 24 weeks, demonstrating significant weight loss compared to placebo. These positive results pave the way for a pivotal phase III study, underscoring ongoing innovation in obesity therapeutics driven by GLP-1 based modalities.